NCT05580341进行中（未招募）3 期
A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- Geometric Mean Titers (GMT) of HPV neutralizing antibodies
研究概览
简要总结
This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 26 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy female 16-26 years of age
- •16-17 years old subjects and their guardians able to provide legal identification; 18-26 years old subjects able to provide their legal identification;
- •Able to understand (not illiterate) and sign the informed consent;
- •Able to make a decision to participate in the clinical trial and the subject agrees to participate in the clinical trial;
- •Women of child-bearing age (WOCBA): subjects must have a negative urine pregnancy test result, have used effective contraceptive measures within 2 weeks before enrollment, have no pregnancy plans, and agree to use adequate contraceptive precautions from enrollment to the 7th month (one month after full immunization).
排除标准
- •Abnormal cervical cancer screen test results (ASC-US or worse), history of HPV infection, history of abnormal cervical biopsy results, or history of genital warts;
- •Subjects with severe congenital malformations or that cause serious organ damage, developmental disorders, genetic defects, or severe malnutrition;
- •Subjects have received a marketed HPV vaccine or participated in an HPV vaccine clinical trial, or participated in clinical trials of other vaccines within the past 6 months;
- •Fever prior to vaccination (axillary body temperature ≥37.3℃);
- •History of severe allergic reaction that required medical intervention (such as swelling of the mouth and throat, dyspnea, hypotension or shock, etc.);
- •History of allergic to vaccine, or to any ingredient of vaccine (Aluminum phosphate adjuvant, sodium chloride, histidine, polysorbate 80),or history of severe adverse reaction
- •History of epilepsy, psychosis, major depression requiring medication, seizures, convulsions, or family history of mental illness
- •Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose
- •History of asthma, thyroidectomy, angioedema, severe liver, kidney, or cardiovascular disease, diabetes mellitus that can not be controlled by stable doses of insulin, or malignancy;
- •Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy;
- •Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
- •Acute diseases or acute stage of chronic diseases or use of antipyretic, analgesic drugs (eg: acetaminophen, ibuprofen, aspirin, etc.) and anti-allergic drugs (such as: loratadine, cetirizine, etc.) within 3 days preceding the vaccination;
- •Untreated/uncontrolled hypertension before vaccination (16-17 years of age > 120 mmHg and / or diastolic blood pressure > 80 mmHg; 18-26 years of age with physical examination systolic blood pressure ≥140 mmHg and / or diastolic blood pressure ≥90 mmHg);
- •Subjects who received whole blood, plasma, or immunoglobulin therapy within 3 months prior to vaccination;
- •Received live attenuated vaccine within 28 days prior to vaccination;
- •Received subunits or inactivated vaccines within 14 days prior to vaccination;
- •Breastfeeding or pregnant, or within 6 weeks after the end of pregnancy;
- •According to the judgment of the investigator, subjects who have any other factors that are not suitable for participating in this clinical trial.
结局指标
主要结局
Geometric Mean Titers (GMT) of HPV neutralizing antibodies
时间窗: 30 days postdose 3 (Month 7)
HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 neutralizing antibodies GMT
Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58
时间窗: 30 days postdose 3 (Month 7)
Seroconversion is defined as a participant in PPS who was anti-HPV seronegative at Day 0 (before vaccination) and became seropositive 30days after the third dose (Month 7).
次要结局
- Percentage of subjects reporting solicited general symptoms(0-7 days after each dose)
- Percentage of subjects reporting unsolicited adverse events (AEs)(0-30 days after each dose)
- Percentage of subjects reporting solicited local symptoms(0-7 days after each dose)
- Percentage of subjects reporting serious adverse events (SAEs)(Month 0 to Month 12)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 YearsHPV InfectionsCIN1CIN2CIN 3VaIN1VaIN2VaIN3Cervical CancerVulvar CancerGenital WartVIN 1VIN 2VIN 3AISVaginal CancerNCT04895020Shanghai Bovax Biotechnology Co., Ltd.1,200
进行中（未招募）
3 期
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Papillomavirus InfectionsNCT03998254Merck Sharp & Dohme LLC6,000
进行中（未招募）
3 期
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)Papillomavirus InfectionsNCT05285826Merck Sharp & Dohme LLC8,100
已完成
3 期
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesCervical CancerVaginal CancerCIN1CIN2CIN3VaIN1VaIN2VaIN3Genital WartVIN 1VIN 2VIN 3AISVulvar CancerNCT04425291Shanghai Bovax Biotechnology Co., Ltd.1,680
已完成
3 期
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy FemalesHPV InfectionsCIN1CIN2CIN3VaIN1VaIN2VaIN3Cervical CancerVaginal CancerGenital WartVIN 1VIN 2VIN 3Vulvar CancerAISNCT05372016Shanghai Bovax Biotechnology Co., Ltd.1,200